Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 Infection and Severe Disease in Singapore

Abstract Compared to individuals vaccinated with Pfizer-BioNTech/Comirnaty, recipients of Sinovac-CoronaVac and Sinopharm were 2.37 (95% CI 2.29–2.46) and 1.62 (95% CI 1.43–1.85) times more likely to be infected with COVID-19 respectively, while individuals vaccinated with Moderna were 0.42 (95% CI 0.25–0.70) times less likely to develop severe disease.

[1]  M. Muszkat,et al.  Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis , 2021, Scientific Reports.

[2]  M. Al-Tamimi,et al.  Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers , 2021, Vaccines.

[3]  F. Uher,et al.  Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans , 2021, GeroScience.

[4]  S. Truelove,et al.  A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease , 2021, medRxiv.

[5]  David W. McDonald,et al.  Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[6]  A. Okhotin.  Effectiveness of an Inactivated SARS-CoV-2 Vaccine. , 2021, The New England journal of medicine.

[7]  Michael J. Ryan,et al.  Considerations in boosting COVID-19 vaccine immune responses , 2021, The Lancet.

[8]  T. Fiolet,et al.  Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.

[9]  B. Cowling,et al.  Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19 , 2021, The Lancet Microbe.

[10]  E. Undurraga,et al.  Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile , 2021, The New England journal of medicine.